Compounds > flusoxolol
Page last updated: 2024-11-06

flusoxolol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Flusoxolol is a nonselective beta blocker that was originally developed for the treatment of glaucoma. It is a derivative of the beta blocker oxprenolol and is a potent inhibitor of both beta1 and beta2 adrenergic receptors. Flusoxolol is effective in lowering intraocular pressure in patients with glaucoma, but it has been largely replaced by other beta blockers with fewer side effects. Flusoxolol is also studied for its potential anti-inflammatory and neuroprotective effects.'

Cross-References

ID SourceID
PubMed CID71765
CHEMBL ID2114429
SCHEMBL ID1255311
MeSH IDM0132065

Synonyms (14)

Synonym
ro 31-1411
flusoxolol
84057-96-5
(2s)-1-[4-[2-[2-(4-fluorophenyl)ethoxy]ethoxy]phenoxy]-3-(propan-2-ylamino)propan-2-ol
(s)-1-(p-(2-((p-fluorophenethyl)oxy)ethoxy)phenoxy)-3-(isopropylamino)-2-propanol
CHEMBL2114429
flusoxolol [inn:ban]
flusoxololum
flusoxololum [latin]
unii-1gpl60irci
1gpl60irci ,
flusoxolol [inn]
DTXSID70232952
SCHEMBL1255311

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"The pharmacokinetic and pharmacodynamic effects of Ro31-1118 were examined in groups of healthy volunteers."( Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.
Arnold, JM; Brown, AN; Finch, MB; Francis, RJ; Galloway, DB; Harron, DW; McDevitt, DG; O'Connor, PC; Shanks, RG, 1985)		0.27
" The pharmacokinetic data were consistent with a one-compartment model with first-order absorption and a variable time lag."( Ro 31-1118, a new cardioselective beta-adrenoceptor antagonist. Pharmacokinetics and effects on heart rate and blood pressure in mild hypertensives.
Francis, RJ; Harris, RI; Jamieson, M; Miller, A; Petrie, JC; Webster, J, 1985)		0.27
" Plasma concentration data were best described by a linear two-compartment pharmacokinetic model with first order absorption, and the results confirmed linear kinetics."( Pharmacokinetics of single and multiple doses of flusoxolol (Ro 31-1411) in healthy subjects.
Francis, RJ; Galloway, DB; Gillies, HC; Humphreys, JE; Rogers, HJ, 1986)		0.53

Bioavailability

ExcerptReferenceRelevance
" In five subjects studied after both oral and intravenous administration of 20 mg Ro31-1118 the average bioavailability was 57% (range 41-73%)."( Human pharmacokinetic and pharmacodynamic studies on Ro31-1118, a new beta-adrenoceptor antagonist.
Arnold, JM; Brown, AN; Finch, MB; Francis, RJ; Galloway, DB; Harron, DW; McDevitt, DG; O'Connor, PC; Shanks, RG, 1985)		0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID177029Beta agonistic activity as the dose required to increase heart rate by 30 beats/min in anesthetized rats upon intravenous administration1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
beta 1-selective adrenoceptor antagonists. 2. 4-ether-linked phenoxypropanolamines.
AID178339Beta-1 adrenoceptor blocking activity as the dose required to inhibit 50% of tachycardia in anesthetized rats1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
beta 1-selective adrenoceptor antagonists. 2. 4-ether-linked phenoxypropanolamines.
AID41350Beta-2 adrenergic receptor antagonist activity as the dose required to inhibit 50% of vasopressor response in anesthetized rats1983Journal of medicinal chemistry, Nov, Volume: 26, Issue:11
beta 1-selective adrenoceptor antagonists. 2. 4-ether-linked phenoxypropanolamines.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (50.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other3 (50.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
atenolol
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.		3.7521ethanolamines;
monocarboxylic acid amide;
propanolamine		anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic
metoprolol
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.		1.9610aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound		antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic
pindolol
Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.		8.3511indoles;
secondary amine		antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent
ConditionIndicatedRelationship StrengthStudiesTrials
Blood Pressure, High
[description not available]		03.3511
Hypertension
Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more.		03.3511
Action Tremor
[description not available]		03.3511
Tremor
Cyclical movement of a body part that can represent either a physiologic process or a manifestation of disease. Intention or action tremor, a common manifestation of CEREBELLAR DISEASES, is aggravated by movement. In contrast, resting tremor is maximal when there is no attempt at voluntary movement, and occurs as a relatively frequent manifestation of PARKINSON DISEASE.		03.3511